查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1618657

微生物组诊断市场：按产品类型、应用和最终用户划分 - 全球预测 2025-2030

Microbiome Diagnostics Market by Product Type (Instruments, Reagents & Kits), Application (Gastrointestinal Disorders, Infectious Diseases, Metabolic Disorders), End-user - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年微生物组诊断市值为7.9936亿美元，预计到2024年将达到9.6027亿美元，复合年增长率为20.72%，预计到2030年将达到29.8787亿美元。

微生物组诊断专注于分析人类和其他宿主微生物群落的遗传物质，以诊断健康状况并彻底改变个人化医疗。人们越来越认识到微生物组在健康和疾病中发挥的作用，推动了这个市场的需求，微生物组有助于胃肠道、代谢和免疫疾病等领域的早期检测、监测和治疗，我们支持个体化治疗。其应用涵盖医疗保健、製药、农业和生物技术，最终用途为医院、诊断实验室、研究机构和专科诊所。市场开拓是由研究和开发活动的活性化、慢性病患病率的上升以及人们对微生物组在健康中所发挥的重要作用的认识不断提高所推动的。政府投资以及学术机构和生物技术公司之间的合作正在进一步推动进展。然而，市场面临着高测试成本、道德考虑、监管障碍和资料隐私问题等挑战，这可能会阻碍成长。理解复杂的微生物与宿主相互作用以及将研究转化为临床实践的限制带来了额外的挑战。儘管存在这些障碍，但扩大微生物组诊断在精准医学中的应用、开发非侵入性检测方法以及整合人工智慧进行资料分析仍然存在重大机会。公司可以开拓医疗保健基础设施正在发展且医疗需求未开拓领域。创新开发具有成本效益的快速诊断工具并专注于消费者教育宣传活动将有助于提高市场接受度。该市场本质上是动态的，其特点是快速的技术进步以及活跃的新兴企业和老牌公司的竞争格局。公司可以透过专注于协作研究、多组体学方法和提供全面的微生物组分析服务来取得成功。这个快速发展的产业需要敏捷性和警觉性，以利用策略伙伴关係和突破性技术。

主要市场统计
基准年[2023] 7.9936 亿美元
预计年份 [2024] 9.6027亿美元
预测年份 [2030] 2,987,870,000 美元
复合年增长率（%） 20.72%

市场动态：揭示快速发展的微生物组诊断市场的关键市场洞察

供需的动态交互作用正在改变微生物组诊断市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，并了解消费行为及其对製造成本的影响，并更清楚地了解对采购趋势的影响。

  • 市场驱动因素
    • 慢性病盛行率上升以及微生物组诊断剂的重要性
    • 政府对微生物组研究的措施与支持
  • 市场限制因素
    • 缺乏微生物组诊断的报销政策
  • 市场机会
    • 增加微生物组研究的投资
    • 微生物组诊断在个人化治疗开发的潜力不断增长
  • 市场挑战
    • 缺乏针对微生物组的标准化通讯协定和可用疗法

波特的五力：驾驭微生物组诊断市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解微生物组诊断市场的外部影响

外部宏观环境因素在塑造微生物组诊断市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解微生物组诊断市场的竞争格局

对微生物组诊断市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵微生物组诊断市场供应商的绩效评估

FPNV定位矩阵是评估微生物组诊断市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议，描绘微生物组诊断市场的成功之路

对于旨在加强在全球市场的影响力的公司来说，微生物组诊断市场的策略分析至关重要。透过考虑关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 慢性病盛行率上升以及基于微生物组的诊断的重要性
      • 政府对微生物组研究的措施与支持
    • 抑制因素
      • 缺乏基于微生物组的诊断的报销政策
    • 机会
      • 增加微生物组研究的投资
      • 微生物组诊断在开发个人化治疗方法的潜力不断增长
    • 任务
      • 缺乏针对微生物组的标准化通讯协定和可用治疗方法
  • 市场区隔分析
    • 产品类型：需要能够处理复杂分析的准确且有效率的设备。
    • 最终用户：製药和生物技术公司更多地采用微生物组诊断来开发个人化治疗方法
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章微生物组诊断市场：依产品类型

  • 装置
  • 试剂和套件

第七章微生物组诊断市场：依应用分类

  • 胃肠道疾病
  • 感染疾病
  • 代谢紊乱

第 8 章微生物组诊断市场：依最终用户分类

  • 製药和生物技术公司
  • 研究/学术机构

第九章美洲微生物组诊断市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第10章亚太微生物组诊断市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章欧洲、中东和非洲的微生物组诊断市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • 推出目标微生物组分析，这是一种针对健康和疾病的基于途径的微生物组分析服务
    • Evvy 是一家专注于阴道微生物组的精准女性健康Start-Ups，宣布获得 1,400 万美元 A 轮资金筹措
    • Xume 与 Microbiome.in 和 TruDiagno 合作，帮助人们根据肠道微生物组做出选择。
  • 战略分析和建议

公司名单

  • 4D Pharma PLC
  • AOBiome Therapeutics
  • Atlas Biomed
  • BioGaia
  • BIOHM Health
  • Bione Ventures Private Limited
  • DayTwo
  • DNA Genotek Inc. by OraSure Technologies Inc.
  • Du Pont De Nemours and Co.
  • Enterome
  • Evvy
  • Ferring Pharmaceuticals
  • Finch Therapeutics Group
  • Flightpath Biosciences, Inc.
  • Genetic Analysis AS
  • Gnubiotics Sciences
  • International Flavors & Fragrances Inc
  • Luxia Scientific
  • MEtabiomics
  • Microba Life Sciences
  • OptiBiotix Health PLC
  • Osel Inc.
  • Quantbiome, Inc.
  • Rebiotix
  • Second Genome, Inc.
  • Seed Health
  • Seres Therapeutics
  • Sun Genomics
  • Symbiotix Biotherapies,
  • Synlogic, Inc.
  • Synthetic Biologics
  • Vedanta Biosciences, Inc.
  • Viome Life Sciences, Inc.
  • ViThera
  • ViThera Pharmaceuticals, Inc.
  • Yakult Honsha Co.
  • YSOPIA Bioscience
Product Code: MRR-BF5906741E57

The Microbiome Diagnostics Market was valued at USD 799.36 million in 2023, expected to reach USD 960.27 million in 2024, and is projected to grow at a CAGR of 20.72%, to USD 2,987.87 million by 2030.

Microbiome diagnostics focuses on analyzing the genetic material of microbial communities in human and other hosts to diagnose health conditions, offering a revolution in personalized medicine. This market's necessity stems from the growing recognition of the microbiome's role in health and disease, where it aids in early detection, monitoring, and treatment personalization in areas like gastrointestinal, metabolic, and immune disorders. Its applications span healthcare, pharmaceuticals, agriculture, and biotechnology, with end-uses in hospitals, diagnostic labs, research institutions, and specialty clinics. Market growth is driven by increasing research and development activities, the rising prevalence of chronic diseases, and growing awareness of the microbiome's critical health roles. Government investments and collaborations between academic institutions and biotech companies further bolster advancements. However, the market faces challenges such as high testing costs, ethical considerations, regulatory hurdles, and data privacy concerns that may impede growth. Limitations in understanding the complex microbiome-host interactions and translating research into clinical practice pose additional challenges. Despite these hurdles, substantial opportunities exist in expanding the application of microbiome diagnostics in precision medicine, developing non-invasive testing methods, and integrating artificial intelligence for data analysis. Companies can tap into unexplored regions with rising healthcare infrastructure and unmet medical needs. Innovating in developing cost-effective, rapid diagnostic tools and emphasizing consumer awareness campaigns could drive wider market acceptance. The market is inherently dynamic, marked by rapid technological advancements and a competitive landscape with active start-ups and established players. Businesses can succeed by focusing on collaborative research, multi-omic approaches, and offering comprehensive microbiome profiling services. This rapidly evolving sector demands agility and vigilance to capitalize on aimed strategic partnerships and breakthrough technologies.

KEY MARKET STATISTICS
Base Year [2023] USD 799.36 million
Estimated Year [2024] USD 960.27 million
Forecast Year [2030] USD 2,987.87 million
CAGR (%) 20.72%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Microbiome Diagnostics Market

The Microbiome Diagnostics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising prevalence of chronic diseases and significance of microbiome-based diagnostics
    • Government initiatives and support for microbiome research
  • Market Restraints
    • Lack of reimbursement policies for microbiome-based diagnostics
  • Market Opportunities
    • Increasing investment in microbiome-based research
    • Growing potential of microbiome diagnostics in developing personalized treatments
  • Market Challenges
    • Lack of standardized protocols and available therapeutics targeting the microbiome

Porter's Five Forces: A Strategic Tool for Navigating the Microbiome Diagnostics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Microbiome Diagnostics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Microbiome Diagnostics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Microbiome Diagnostics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Microbiome Diagnostics Market

A detailed market share analysis in the Microbiome Diagnostics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Microbiome Diagnostics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Microbiome Diagnostics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Microbiome Diagnostics Market

A strategic analysis of the Microbiome Diagnostics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Microbiome Diagnostics Market, highlighting leading vendors and their innovative profiles. These include 4D Pharma PLC, AOBiome Therapeutics, Atlas Biomed, BioGaia, BIOHM Health, Bione Ventures Private Limited, DayTwo, DNA Genotek Inc. by OraSure Technologies Inc., Du Pont De Nemours and Co., Enterome, Evvy, Ferring Pharmaceuticals, Finch Therapeutics Group, Flightpath Biosciences, Inc., Genetic Analysis AS, Gnubiotics Sciences, International Flavors & Fragrances Inc, Luxia Scientific, MEtabiomics, Microba Life Sciences, OptiBiotix Health PLC, Osel Inc., Quantbiome, Inc., Rebiotix, Second Genome, Inc., Seed Health, Seres Therapeutics, Sun Genomics, Symbiotix Biotherapies,, Synlogic, Inc., Synthetic Biologics, Vedanta Biosciences, Inc., Viome Life Sciences, Inc., ViThera, ViThera Pharmaceuticals, Inc., Yakult Honsha Co., and YSOPIA Bioscience.

Market Segmentation & Coverage

This research report categorizes the Microbiome Diagnostics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product Type, market is studied across Instruments and Reagents & Kits.
  • Based on Application, market is studied across Gastrointestinal Disorders, Infectious Diseases, and Metabolic Disorders.
  • Based on End-user, market is studied across Pharmaceutical & Biotechnology Companies and Research & Academic Institutes.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of chronic diseases and significance of microbiome-based diagnostics
      • 5.1.1.2. Government initiatives and support for microbiome research
    • 5.1.2. Restraints
      • 5.1.2.1. Lack of reimbursement policies for microbiome-based diagnostics
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasing investment in microbiome-based research
      • 5.1.3.2. Growing potential of microbiome diagnostics in developing personalized treatments
    • 5.1.4. Challenges
      • 5.1.4.1. Lack of standardized protocols and available therapeutics targeting the microbiome
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Product Type: Need for accurate and efficient instruments capable of handling complex analyses
    • 5.2.2. End-user: Growing adoption of microbiome diagnostics in pharmaceutical and biotechnology companies to develop personalized therapies
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Microbiome Diagnostics Market, by Product Type

  • 6.1. Introduction
  • 6.2. Instruments
  • 6.3. Reagents & Kits

7. Microbiome Diagnostics Market, by Application

  • 7.1. Introduction
  • 7.2. Gastrointestinal Disorders
  • 7.3. Infectious Diseases
  • 7.4. Metabolic Disorders

8. Microbiome Diagnostics Market, by End-user

  • 8.1. Introduction
  • 8.2. Pharmaceutical & Biotechnology Companies
  • 8.3. Research & Academic Institutes

9. Americas Microbiome Diagnostics Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Microbiome Diagnostics Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Microbiome Diagnostics Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. Launch of "Targeted Microbiome Profiling", a pathway-based microbiome profiling service for health and disease
    • 12.3.2. Evvy, Precision Women's Health Startup focused on the Vaginal Microbiome, Announces USD 14 million Series A
    • 12.3.3. Xume partners with Microbiome.in and TruDiagno to help people make gut microbiome-informed choices
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. 4D Pharma PLC
  • 2. AOBiome Therapeutics
  • 3. Atlas Biomed
  • 4. BioGaia
  • 5. BIOHM Health
  • 6. Bione Ventures Private Limited
  • 7. DayTwo
  • 8. DNA Genotek Inc. by OraSure Technologies Inc.
  • 9. Du Pont De Nemours and Co.
  • 10. Enterome
  • 11. Evvy
  • 12. Ferring Pharmaceuticals
  • 13. Finch Therapeutics Group
  • 14. Flightpath Biosciences, Inc.
  • 15. Genetic Analysis AS
  • 16. Gnubiotics Sciences
  • 17. International Flavors & Fragrances Inc
  • 18. Luxia Scientific
  • 19. MEtabiomics
  • 20. Microba Life Sciences
  • 21. OptiBiotix Health PLC
  • 22. Osel Inc.
  • 23. Quantbiome, Inc.
  • 24. Rebiotix
  • 25. Second Genome, Inc.
  • 26. Seed Health
  • 27. Seres Therapeutics
  • 28. Sun Genomics
  • 29. Symbiotix Biotherapies,
  • 30. Synlogic, Inc.
  • 31. Synthetic Biologics
  • 32. Vedanta Biosciences, Inc.
  • 33. Viome Life Sciences, Inc.
  • 34. ViThera
  • 35. ViThera Pharmaceuticals, Inc.
  • 36. Yakult Honsha Co.
  • 37. YSOPIA Bioscience

LIST OF FIGURES

  • FIGURE 1. MICROBIOME DIAGNOSTICS MARKET RESEARCH PROCESS
  • FIGURE 2. MICROBIOME DIAGNOSTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS MICROBIOME DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS MICROBIOME DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES MICROBIOME DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES MICROBIOME DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC MICROBIOME DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC MICROBIOME DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA MICROBIOME DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA MICROBIOME DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. MICROBIOME DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. MICROBIOME DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. MICROBIOME DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. MICROBIOME DIAGNOSTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY GASTROINTESTINAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. AMERICAS MICROBIOME DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS MICROBIOME DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS MICROBIOME DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS MICROBIOME DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 21. ARGENTINA MICROBIOME DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 22. ARGENTINA MICROBIOME DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 23. ARGENTINA MICROBIOME DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 24. BRAZIL MICROBIOME DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 25. BRAZIL MICROBIOME DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 26. BRAZIL MICROBIOME DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 27. CANADA MICROBIOME DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. CANADA MICROBIOME DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 29. CANADA MICROBIOME DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 30. MEXICO MICROBIOME DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. MEXICO MICROBIOME DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 32. MEXICO MICROBIOME DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 33. UNITED STATES MICROBIOME DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. UNITED STATES MICROBIOME DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES MICROBIOME DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES MICROBIOME DIAGNOSTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 37. ASIA-PACIFIC MICROBIOME DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. ASIA-PACIFIC MICROBIOME DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC MICROBIOME DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC MICROBIOME DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 41. AUSTRALIA MICROBIOME DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. AUSTRALIA MICROBIOME DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 43. AUSTRALIA MICROBIOME DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 44. CHINA MICROBIOME DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. CHINA MICROBIOME DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 46. CHINA MICROBIOME DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 47. INDIA MICROBIOME DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. INDIA MICROBIOME DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 49. INDIA MICROBIOME DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 50. INDONESIA MICROBIOME DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. INDONESIA MICROBIOME DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 52. INDONESIA MICROBIOME DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 53. JAPAN MICROBIOME DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. JAPAN MICROBIOME DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 55. JAPAN MICROBIOME DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 56. MALAYSIA MICROBIOME DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. MALAYSIA MICROBIOME DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 58. MALAYSIA MICROBIOME DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 59. PHILIPPINES MICROBIOME DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. PHILIPPINES MICROBIOME DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 61. PHILIPPINES MICROBIOME DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 62. SINGAPORE MICROBIOME DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. SINGAPORE MICROBIOME DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 64. SINGAPORE MICROBIOME DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 65. SOUTH KOREA MICROBIOME DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. SOUTH KOREA MICROBIOME DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 67. SOUTH KOREA MICROBIOME DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 68. TAIWAN MICROBIOME DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. TAIWAN MICROBIOME DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 70. TAIWAN MICROBIOME DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 71. THAILAND MICROBIOME DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. THAILAND MICROBIOME DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 73. THAILAND MICROBIOME DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 74. VIETNAM MICROBIOME DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. VIETNAM MICROBIOME DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 76. VIETNAM MICROBIOME DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 77. EUROPE, MIDDLE EAST & AFRICA MICROBIOME DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA MICROBIOME DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA MICROBIOME DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA MICROBIOME DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 81. DENMARK MICROBIOME DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. DENMARK MICROBIOME DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 83. DENMARK MICROBIOME DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 84. EGYPT MICROBIOME DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. EGYPT MICROBIOME DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 86. EGYPT MICROBIOME DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 87. FINLAND MICROBIOME DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. FINLAND MICROBIOME DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 89. FINLAND MICROBIOME DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 90. FRANCE MICROBIOME DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. FRANCE MICROBIOME DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 92. FRANCE MICROBIOME DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 93. GERMANY MICROBIOME DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. GERMANY MICROBIOME DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 95. GERMANY MICROBIOME DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 96. ISRAEL MICROBIOME DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. ISRAEL MICROBIOME DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 98. ISRAEL MICROBIOME DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 99. ITALY MICROBIOME DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. ITALY MICROBIOME DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 101. ITALY MICROBIOME DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 102. NETHERLANDS MICROBIOME DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. NETHERLANDS MICROBIOME DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 104. NETHERLANDS MICROBIOME DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 105. NIGERIA MICROBIOME DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. NIGERIA MICROBIOME DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 107. NIGERIA MICROBIOME DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 108. NORWAY MICROBIOME DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. NORWAY MICROBIOME DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 110. NORWAY MICROBIOME DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 111. POLAND MICROBIOME DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. POLAND MICROBIOME DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 113. POLAND MICROBIOME DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 114. QATAR MICROBIOME DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. QATAR MICROBIOME DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 116. QATAR MICROBIOME DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 117. RUSSIA MICROBIOME DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. RUSSIA MICROBIOME DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 119. RUSSIA MICROBIOME DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 120. SAUDI ARABIA MICROBIOME DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. SAUDI ARABIA MICROBIOME DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 122. SAUDI ARABIA MICROBIOME DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 123. SOUTH AFRICA MICROBIOME DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. SOUTH AFRICA MICROBIOME DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH AFRICA MICROBIOME DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 126. SPAIN MICROBIOME DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. SPAIN MICROBIOME DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 128. SPAIN MICROBIOME DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 129. SWEDEN MICROBIOME DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. SWEDEN MICROBIOME DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 131. SWEDEN MICROBIOME DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 132. SWITZERLAND MICROBIOME DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. SWITZERLAND MICROBIOME DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 134. SWITZERLAND MICROBIOME DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 135. TURKEY MICROBIOME DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. TURKEY MICROBIOME DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 137. TURKEY MICROBIOME DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 138. UNITED ARAB EMIRATES MICROBIOME DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. UNITED ARAB EMIRATES MICROBIOME DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED ARAB EMIRATES MICROBIOME DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED KINGDOM MICROBIOME DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED KINGDOM MICROBIOME DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED KINGDOM MICROBIOME DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 144. MICROBIOME DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 145. MICROBIOME DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023